Linnaeus Reports First Patients Dosing with LNS8801 + Keytruda (pembrolizumab) in P-I/II Study for Advanced Cancer

 Linnaeus Reports First Patients Dosing with LNS8801 + Keytruda (pembrolizumab) in P-I/II Study for Advanced Cancer

Linnaeus Reports First Patients Dosing with LNS8801 + Keytruda (pembrolizumab) in P-I/II Study for Advanced Cancer

Shots:

  • The first patient has been dosed in P-l/ll adaptive-design study assessing the safety, tolerability, pharmacokinetics, and antitumor activity of LNS8801+ Keytruda (pembrolizumab) in patients who had previous clinical benefit from immune checkpoint inhibitors and then subsequently progressed
  • The initiation of the study follows the identification of the RP2D in the ongoing study of LNS8801. The company anticipates opening several more phase 2 dose-expansion cohorts exploring LNS8801 activity as a monothx. and in combination with other compounds in 2021
  • LNS8801 (PO) is a bioavailable small molecule that is a highly specific and potent agonist of the GPER and has demonstrated target engagement and clinical benefit in advanced cancer patients. P-l/ll study’s results are anticipated to be presented in a peer-reviewed setting in 2021

    Click here to­ read full press release/ article | Ref: PRNewswire | Image: PRNewswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post